Current Report Filing (8-k)
September 17 2020 - 6:39AM
Edgar (US Regulatory)
0001651407
false
0001651407
2020-09-17
2020-09-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the
Securities Exchange
Act of 1934
Date of report
(Date of earliest event reported): September
17, 2020
Checkpoint Therapeutics, Inc.
(Exact Name of Registrant
as Specified in Charter)
Delaware
|
|
001-38128
|
|
47-2568632
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal
Executive Offices)
(781) 652-4500
(Registrant’s
telephone number, including area code)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425).
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2b under the
Exchange Act (17 CFR 240.14d-2(b)).
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)).
|
Securities registered
pursuant to Section 12(b) of the Exchange Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
|
CKPT
|
|
NASDAQ Capital Market
|
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On September 17, 2020, Checkpoint Therapeutics, Inc. issued
a press release announcing updated interim results from its registration-enabling Phase 1 clinical trial of anti-PD-L1 antibody
cosibelimab in patients with metastatic cutaneous squamous cell carcinoma. A copy of such press release is being filed as Exhibit
99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is filed herewith:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 17, 2020
|
Checkpoint Therapeutics, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
By
|
/s/ James F. Oliviero
|
|
|
|
James F. Oliviero
|
|
|
|
President and Chief Executive Officer
|
|
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Sep 2023 to Sep 2024